Neoadjuvant chemotherapy in breast cancer - Insights from the German experience

Breast Cancer

Volumn 19, Issue 4, 2012, Pages 282-288

  Von Minckwitz, Gunter ^a  

^a GBG Forschungs GmbH   (Germany)

Author keywords

Breast cancer; Chemotherapy; Ki 67; Molecular subtypes; Neoadjuvant; Pathological complete response

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INIPARIB; KI 67 ANTIGEN; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PERTUZUMAB; PROGESTERONE RECEPTOR; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CONFERENCE PAPER; DIMERIZATION; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; GERMANY; HUMAN; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TISSUE MICROARRAY; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; METHODOLOGY; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; KI-67 ANTIGEN; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84876431891     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0393-7     Document Type: Conference Paper

References (21)

1. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796-804.
2. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-47.
3. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. NEJM. 2012;366:2438-41.
4. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377-84.
5. Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135-44.
6. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
7. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205-14.
8. O'Shaughnessy J, Schwartzberg MA, Danso HS et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29: suppl (Abstr 1007).
9. Llombard A, Lluch A, Villanueva C et al. SOLTI NeoPARP: a phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC). J Clin Oncol 2012; 30 (suppl; abstr 1011).
10. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299-309.
11. Gerber B, Eidtman H, Rezai M et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: seconday endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol 2011; 29: suppl (Abstr 1006).
12. Gianni L, Bianchini G, Kiermaier A, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-Arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC). Cancer Res. 2011;71(Suppl 24):Abst S5-1.
13. Huober J, Loibl S, Untch M, et al. New molecular biomarkers for resistance to trastuzumab-based in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Res 2010;70 (Suppl 24): Abstract PD02-06.
14. Loibl S, Bruey JM, von Minckwitz G, et al. Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: a translational investigation from the neoadjuvant GeparQuattro study. J Clin Oncol 2011;29 (suppl): abstr 530.
15. Guarneri V et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2 - positive operable breast cancer: results of the randomized phase II CHER-LOB study. JCO published online on April 9, 2012. doi: 10.1200/JCO.2011.39.0823.
16. von Minckwitz G, Muller BM, Loibl S, et al. Cytoplasmic poly(ADP-ribose)polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011;29:2150-7.
17. von Minckwitz G, Müller B, Blohmer JU, et al. Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. J Clin Oncol. 2012;30: (suppl; abstr 1023).
18. von Minckwitz G, Kummel S, Vogel P, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst. 2008;100:552-62.
19. von Minckwitz G, Kümmel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100:542-51.
20. von Minckwitz G, Blohmer JU, Costa SD, et al. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients - results of the GeparTrio trial. Cancer Res. 2011;71(24 Suppl.):103s.
21. von Minckwitz G, Kaufmann M, Kümmel S, et al. Local recurrence risk after neoadjuvant chemotherapy. Pooled analysis on 5477 breast cancer patients. Cancer Res. 2011;71(24 suppl.):142s.